Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 5 |
| List of Tables | 10 | 1 |
| List of Figures | 10 | 1 |
| Diabetes Therapeutics Market in India to 2018 - Overview | 11 | 1 |
| Diabetes Mellitus - A Global Overview | 11 | 1 |
| Diabetes Therapeutics Market in India - Introduction | 12 | 5 |
| Type 1 Diabetes Mellitus | 12 | 1 |
| People at Risk | 12 | 1 |
| Risk Factors for Type 1 Diabetes | 12 | 1 |
| Symptoms | 12 | 1 |
| Type 2 Diabetes Mellitus | 13 | 1 |
| People at Risk | 13 | 1 |
| Risk Factors for Type 2 Diabetes | 13 | 1 |
| Symptoms | 13 | 1 |
| Gestational Diabetes Mellitus | 13 | 1 |
| Risk Factors for Gestational Diabetes Mellitus | 13 | 1 |
| Diagnosis of Diabetes Mellitus | 14 | 1 |
| Diabetes Treatment Guidelines - India | 15 | 1 |
| Introduction | 15 | 1 |
| Prevention of Diabetes | 15 | 1 |
| Diabetes Treatment | 15 | 1 |
| Non-Pharmacological Treatment | 16 | 1 |
| Pharmacological Treatment | 16 | 1 |
| Diabetes Mellitus Complications | 16 | 1 |
| Diabetes Therapeutics Market in India to 2018 - Major Drug Classes | 17 | 8 |
| Sulfonylureas | 17 | 1 |
| Introduction | 17 | 1 |
| Mechanism of Action | 17 | 1 |
| Major Drugs | 18 | 1 |
| Thiazolidinediones | 18 | 1 |
| Introduction | 18 | 1 |
| Mechanism of Action | 18 | 1 |
| Example | 18 | 1 |
| Biguanides | 19 | 1 |
| Introduction | 19 | 1 |
| Mechanism of Action | 19 | 1 |
| Drug Products | 19 | 1 |
| Meglitinides | 20 | 1 |
| Introduction | 20 | 1 |
| Mechanism of Action | 20 | 1 |
| Major Drugs | 20 | 1 |
| Alpha-Glucosidase Inhibitors | 21 | 1 |
| Introduction | 21 | 1 |
| Mechanism of Action | 21 | 1 |
| Major Drugs | 21 | 1 |
| Glucagon-Like Peptide Analogs and Agonists | 22 | 1 |
| Description | 22 | 1 |
| Mechanism of Action | 22 | 1 |
| Major Drugs | 22 | 1 |
| Dipeptidyl Peptidase-4 Inhibitors | 22 | 1 |
| Description | 22 | 1 |
| Mechanism of Action | 22 | 1 |
| Major Drugs | 23 | 1 |
| Glucagon-Like Peptide-1 Analogs vs. Dipeptidyl Peptidase-4 Inhibitors | 23 | 1 |
| Insulin Preparations | 23 | 1 |
| Introduction | 23 | 1 |
| Types of Insulin | 23 | 1 |
| Pre-mixed Insulin | 24 | 1 |
| Long-acting Analogs | 24 | 1 |
| Rapid-acting Analogs | 24 | 1 |
| Others | 24 | 1 |
| Diabetes Therapeutics Market in India to 2018 - Epidemiology | 25 | 5 |
| Introduction | 25 | 2 |
| Diabetes Population in India | 27 | 2 |
| Diagnosed Population | 29 | 1 |
| Treated Population | 29 | 1 |
| Diabetes Therapeutics Market in India to 2018 - Revenue Forecasts | 30 | 3 |
| Introduction | 30 | 1 |
| Oral Anti-Diabetics Market | 31 | 1 |
| Insulin Market | 31 | 1 |
| Annual Cost of Therapy | 32 | 1 |
| Diabetes Therapeutics Market in India to 2018 - Economic Burden of Diabetes in India | 33 | 2 |
| Economic Burden of Diabetes in India | 33 | 1 |
| Introduction | 33 | 1 |
| Healthcare Expenditure on Diabetes in India | 33 | 1 |
| Collaborative Efforts Necessary to Address the Rising Burden of Diabetes | 34 | 1 |
| Diabetes Therapeutics Market in India to 2018 - Drivers and Barriers | 35 | 3 |
| Market Drivers | 35 | 1 |
| Aging Population, Sedentary Lifestyle and Unhealthy Diet is Driving the Diabetic Population in India | 35 | 1 |
| Promising Molecules Offering Improved Clinical Outcomes Could Increase Patient Base on Therapy | 35 | 1 |
| Untapped Areas Offer Promising Opportunities to Pharmaceutical Companies | 36 | 1 |
| Market Barriers | 36 | 1 |
| Low Diagnosis and Prescription Rate | 36 | 1 |
| Highly Competitive Market Driven by Generics and Branded Generics Increases Pricing Pressure | 36 | 1 |
| High Out-of-Pocket and Low Healthcare Expenditure on Diabetes | 37 | 1 |
| Diabetes Therapeutics Market in India to 2018 - Unmet Needs | 38 | 1 |
| Introduction | 38 | 1 |
| High Cost of Therapy and Drug Safety Issues Affect Patient Compliance | 38 | 1 |
| Unmet Need Creates Opportunities for Pharmaceutical Companies | 38 | 1 |
| Diabetes Therapeutics Market in India to 2018 - Product Pipeline Analysis | 39 | 4 |
| Profiles of Promising Molecules in R&D Development | 40 | 1 |
| IN-105 (Oral Insulin) | 40 | 1 |
| Product Description | 40 | 1 |
| Mechanism of Action | 40 | 1 |
| R&D Progress | 40 | 1 |
| NN9068/IDegLira/degludec +/- liraglutide | 40 | 1 |
| Product Description | 40 | 1 |
| Mechanism of Action | 41 | 1 |
| R&D Progress | 41 | 1 |
| Dapagliflozin | 41 | 1 |
| Product Description | 41 | 1 |
| Mechanism of Action | 41 | 1 |
| R&D Progress | 41 | 1 |
| Canagliflozin/TA-7284 | 42 | 1 |
| Product Description | 42 | 1 |
| Mechanism of Action | 42 | 1 |
| Lixisenatide | 42 | 1 |
| Product Description | 42 | 1 |
| Mechanism of Action | 42 | 1 |
| Alogliptin | 42 | 1 |
| Product Description | 42 | 1 |
| Mechanism of Action | 42 | 1 |
| Diabetes Therapeutics Market in India to 2018 - Case Studies | 43 | 3 |
| Avandia Fallout Impact | 43 | 1 |
| Introduction | 43 | 1 |
| Cardiovascular Safety Issues | 43 | 1 |
| Impact on GlaxoSmithKline | 43 | 1 |
| Impact on Drug Approvals | 43 | 1 |
| Januvia from Merck an Example that Patented Products can succeed in India | 44 | 1 |
| Introduction | 44 | 1 |
| Improved Pharmacological Effect of DPP-4 Inhibitors Helped Rapid Adoption | 44 | 1 |
| Januvia and Janumet a New Growth Engine for Merck | 44 | 1 |
| Robust Approach Needed to Market a New Drug Product in India | 44 | 1 |
| Excellent Commercialization Strategy | 45 | 1 |
| Conclusion | 45 | 1 |
| Diabetes Therapeutics Market in India to 2018 - Major Trends and Issues | 46 | 9 |
| Biguanides Class is dominated by Generics | 46 | 1 |
| Evolving Oral Hypoglycemic Agents Resulting in Smaller Market Share Sulfonylureas | 46 | 1 |
| Increasing Competition in Dipeptidyl Peptidase-4 Inhibitor Class | 46 | 1 |
| DPP-4 Inhibitors Likely to Face Potential Competition from GLP-1 Agonists | 46 | 1 |
| Thiazolidinedione Class to Face Impact of Avandia Fallout | 47 | 1 |
| GLP-1 Agonists Must Demonstrate Better Safety and Efficacy Profiles to Compete with other Oral Hypoglycemic Class | 47 | 1 |
| Fierce Competition in the Insulin Market is Likely to Increase | 48 | 1 |
| Is Oral Insulin the Next Big Thing in the Insulin Market? | 48 | 1 |
| Introduction | 48 | 1 |
| Oral Insulin Not for All | 48 | 1 |
| Challenges to Overcome | 48 | 1 |
| Beating the Body s Defense Mechanism | 48 | 1 |
| Dosing a Problems | 48 | 1 |
| Would it lead to Market Cannibalization? | 49 | 1 |
| India Diabetes Market: Setting up for the Biosimilars? | 49 | 1 |
| Introduction | 49 | 1 |
| Insulin Biosimilar Market | 49 | 1 |
| Sanofi s Lantus a Lucrative Target | 49 | 1 |
| Need for Dose Adjustments would Discourage Uptake of Biosimilars | 50 | 1 |
| Price Discounts Alone would be Insufficient | 50 | 1 |
| Strong Brand Promotion would be Necessary for Insulin Biosimilars | 50 | 1 |
| Collaborations and Licensing Agreements are Key | 50 | 1 |
| Conclusion | 51 | 1 |
| Sodium Glucose Co-Transporter2 Inhibitors: A New Class to Hit the Market? | 51 | 1 |
| Glucokinase Activators | 51 | 1 |
| Stem Cell Therapies: The Next Prospective Therapy for Diabetes? | 52 | 1 |
| Introduction | 52 | 1 |
| What are Stem Cells? | 52 | 1 |
| Stem Cell Therapies and Diabetes | 52 | 1 |
| Conclusion | 52 | 1 |
| Price Discounts a Decisive Factor in the Increasingly Competitive Anti-Diabetes Market | 53 | 1 |
| Favorable Government Polices to Promote Generics | 53 | 1 |
| Strategic Consolidation to Increase Growth Prospects | 54 | 1 |
| Introduction | 54 | 1 |
| Shift of Focus towards Rural and Class II-IV Towns | 54 | 1 |
| Diabetes Therapeutics Market in India to 2018 - Competitive Landscape | 55 | 9 |
| Novartis India Limited (Novartis India) | 55 | 1 |
| Novo Nordisk India Private Limited (Novo) | 56 | 1 |
| Eli Lilly and Company (India) Pvt. Ltd. (Eli Lilly) | 57 | 1 |
| Merck Sharp Dohme India | 57 | 1 |
| Abbott India Limited (Abbott India) | 58 | 1 |
| Sun Pharmaceutical Industries Limited (Sun Pharma) | 59 | 1 |
| USV Limited | 60 | 1 |
| Wockhardt Limited (Wockhardt) | 61 | 1 |
| Sanofi India Limited | 62 | 1 |
| Biocon Limited (Biocon) | 63 | 1 |
| Diabetes Therapeutics Market in India to 2018 - Strategic Consolidations | 64 | 3 |
| Introduction | 64 | 1 |
| Diabetology Entered into Licensing Agreement with USV for Capsulin on July 31, 2012 | 64 | 1 |
| Merck Sharp &Dohme Entered into Co-Marketing Agreement with Sun Pharma on April 25, 2011 | 64 | 1 |
| Eli Lilly and Company (India) Entered into Co-Promotion Agreement with Lupin on July 29, 2011 | 65 | 1 |
| Sheffield Bio-Science Entered into Collaboration with Wockhardt on February 21, 2011 | 65 | 1 |
| Eli Lilly Entered into Co-Promotion Agreement with Boehringer Ingelheim for Humalog and Linagliptin on October 3, 2011 | 65 | 1 |
| Novartis India Entered into Co-Marketing Agreement with USV on December 31, 2008 | 65 | 1 |
| Pfizer-Biocon Deal Called Off in March 2012 | 66 | 1 |
| Impact Analysis | 66 | 1 |
| Diabetes Therapeutics Market in India to 2018 - Appendix | 67 | 8 |
| Market Definitions | 67 | 1 |
| Abbreviations | 67 | 1 |
| Bibliography | 68 | 1 |
| Research Methodology | 69 | 2 |
| Coverage | 69 | 1 |
| Secondary Research | 70 | 1 |
| Primary Research | 70 | 1 |
| Therapeutic Landscape | 71 | 3 |
| Market | 73 | 1 |
| Geographical Landscape | 74 | 1 |
| Pipeline Analysis | 74 | 1 |
| Competitive Landscape | 74 | 1 |
| Expert Panel Validation | 74 | 1 |
| Contact Us | 74 | 1 |
| Disclaimer | 74 | 1 |